NGAM Advisors L.P. grew its stake in Eli Lilly and Company (NYSE:LLY) by 9.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,071 shares of the company’s stock after purchasing an additional 3,715 shares during the period. NGAM Advisors L.P.’s holdings in Eli Lilly and were worth $3,380,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of LLY. Vanguard Group Inc. raised its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after acquiring an additional 2,181,701 shares during the last quarter. BlackRock Inc. raised its stake in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares during the last quarter. State Street Corp raised its stake in shares of Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after acquiring an additional 651,424 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after acquiring an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC raised its stake in shares of Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after acquiring an additional 237,619 shares during the last quarter. Institutional investors and hedge funds own 75.77% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) traded down 0.76% on Friday, hitting $82.44. 5,374,504 shares of the stock were exchanged. The company has a 50-day moving average price of $80.89 and a 200-day moving average price of $82.06. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The firm has a market cap of $86.97 billion, a PE ratio of 35.67 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date was Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.
A number of research analysts recently issued reports on LLY shares. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a report on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating on shares of Eli Lilly and in a report on Tuesday, May 30th. BMO Capital Markets reiterated an “underperform” rating and issued a $71.00 price target (down previously from $73.00) on shares of Eli Lilly and in a report on Wednesday, September 6th. Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a research report on Wednesday, July 26th. Finally, TheStreet lowered shares of Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $88.27.
In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last quarter, insiders sold 825,000 shares of company stock valued at $68,456,650. Company insiders own 0.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Position Lifted by NGAM Advisors L.P.” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/09/17/eli-lilly-and-company-lly-position-lifted-by-ngam-advisors-l-p.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.